2018 opened with elevated U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit.
U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light — more than double the previous year — while the figure also rose in the EU.
The United States should take action to reduce demand for the drugs fueling its deadly opioid crisis, a top Chinese drug control official said.
Teva Pharmaceutical Industries Ltd. announced the exclusive launch of a generic version of Reyataz (atazanavir) capsules in the U.S.
Amgen Inc. said a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.
The trade group representing U.S. drugmakers filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices.
Growth in healthcare spending in the United States slowed in 2016 following two years of expansion under the Affordable Care Act.
The U.S. government is considering setting new payment methods aimed at curbing costs for Medicare and Medicaid coverage of breakthrough medical treatments with very high prices, particularly novel gene-based therapies for cancer and other diseases, a top health official said.
Alex Azar – a former drug industry exec who Republicans nominated to run the Department of Health and Human Services – promised to lower drug prices that he said are too high, saying he would look at abuse of patent laws that delays generic competition.